Laekna Advances Obesity Drug LAE102 With Positive Phase I DataTip Ranks·18 hours ago02105+1.71%LLY-1.06%
Laekna FY26 H1 net loss narrows to RMB 2.55 million; revenue rises to RMB 150.28 millionPUBT·19 hours ago02105+1.71%
New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products AdministrationUnusual Whales·Aug 11 at 09:47 PM02105+1.71%
Laekna says China regulator accepts NDA for afuresertib in HR+/HER2- breast cancerPUBT·Aug 11 at 07:19 PM02105+1.71%
Laekna files HKEX next-day disclosure return, reports share repurchase for cancellationPUBT·Jul 13 at 05:36 AM02105+1.71%
Laekna files HKEX next-day disclosure return reporting share repurchase for cancellationPUBT·Jul 10 at 06:29 AM02105+1.71%
Laekna files HKEX next-day disclosure return disclosing share repurchase for cancellationPUBT·Jul 9 at 05:50 AM02105+1.71%
Laekna names Ke Chenyu sole company secretary after Ho Wing Nga resignationPUBT·Jun 29 at 08:59 AM02105+1.71%
